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SUMMARY
A 70- year- old man was admitted to our COVID-19 ward 
with thoracalgia, productive mucus cough, fatigue and 
erythematous–violaceous macules on the inner side of 
feet and interdigital regions. The patient was started on 
oxygen and dexamethasone. On the day of discharge, 
he maintained the skin changes despite the resolution 
of COVID-19 symptoms. A 57- year- old woman initially 
presented with diffuse urticarial rash on the cervical and 
chest region. Oral cetirizine was started, and pruritus 
improved. Thirty days after the discharge, the patient 
maintained the rash, but without pruritus. A 49- year- 
old man was admitted with thoracalgia, shortness of 
breath, dry cough and urticarial rash on the cervical and 
chest region. The patient was treated with cetirizine. 
The pruritus improved, and 5 days after discharge, the 
urticarial areas completely disappeared.
BACKGROUND
In December 2019, in the Chinese city of Wuhan, 
were reported the first cases of unexplained pneu-
monia,1 caused by a new infectious pathogen named 
SARS- CoV-2.2 The resulting disease was called 
COVID-193 and has become a global health threat, 
infecting 118 058 503 individuals, and resulting in 
2 621 046 deaths by 12 March 2021.4
With the global increase in the number of 
SARS- CoV-2 infections, there has been a rising 
frequency of cutaneous manifestations with 
different morphology types. Mechanisms respon-
sible for the skin rash in SARS- CoV-2 have been 
formulated, including direct virus infection of an 
open wound of the skin, immune system responses 
or iatrogenic drug introduction.5
In a prospective nationwide case collection study 
in Spain conducted by Galván et al, which included 
375 patients, the authors described five clinical 
patterns associated with COVID-19. These patterns 
comprised acral areas of erythema–oedema with 
some vesicles or pustules (pseudochilblain), other 
vesicular eruptions, urticarial lesions, other macu-
lopapules, and livedos or necrosis.6 Their frequency 
and timing in the disease’s natural course are still 
challenging to determine.7 However, some authors 
reported maculopapular eruptions, pseudochilblain 
and urticarial rash to be the most common muco-
cutaneous manifestations in COVID-19,8 9 devel-
oping few days before the onset of the systemic 
symptoms. Erythematous rash and localised or 
generalised urticaria appear to be the most shared 
cutaneous manifestations in patients with acute 
severe infection, although the underlying cause, 
such as viral infection or drug reaction may be 
challenging to identify.10 For example, hydroxy-
chloroquine, experimentally used for the treatment 
of COVID-19 in the early days of the pandemic, is 
associated with a generalised pustular rash.8 10
Since cutaneous manifestations of COVID-19 
seem to be self- resolving, the treatment recommen-
dations support symptoms control with analgesics, 
corticosteroids or non- steroidal anti- inflammatory 
drugs.11
FIRST CASE
Case presentation
A 70- year- old man with a medical history of arte-
rial hypertension and type 2 diabetes mellitus was 
admitted to our COVID-19 ward. The diagnosis of 
SARS- CoV-2 infection by a positive nasopharyngeal 
swab test was made while he was asymptomatic, as 
he had high- risk contact with a family member who 
had been diagnosed with COVID-19. Subsequently, 
the patient began to experience thoracalgia, produc-
tive mucus cough and progressive fatigue and was 
admitted 8 days after the SARS- CoV-2 positive 
test to the hospital with bilateral pneumonia. He 
presented with erythematous–violaceous macules 
on the inner side of his feet (figure 1) and interdig-
ital regions (figures 2 and 3).
Investigations
Arterial blood gas analysis revealed pH 7.51, pCO2 
30.5 mm Hg, pO2 59.9 mm Hg, oxygen saturation 
93.7%, HCO3
− 26.2 mEq/L and lactate 1.2 mg/
dL. Laboratory tests showed lymphopenia 800/
µL, increased D- dimers (4693 ng/mL), hypona-
traemia (123 mEq/L) and hypochloraemia (90 
mEq/L), increased gamma- glutamyltransferase 
(GGT) (88.9 U/L) and lactate dehydrogenase 
(LDH) (392 U/L), and elevated C reactive protein 
(CRP) (62.50 mg/L) and ferritin (1675 ng/mL). The 
platelet count and renal function were both normal. 
Chest radiography revealed peripheral cotton infil-
trates in both lung bases with greater extension in 
the right base (figure 4).
Treatment
According to the recommended protocol by our 
government’s health authority, Directorate- General 
of Health, the patient was started on oxygen and 
dexamethasone. Prophylactic enoxaparin, sodium 
chloride, furosemide, perindopril, paracetamol and 
metamizole were also administered.
Outcome and follow-up
In the following days, the patient promptly recov-
ered, and we have been able to gradually reduce 
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oxygen flow. On the day of discharge, the patient maintained the 
skin changes despite the resolution of COVID-19 symptoms. In 
the re- evaluation consultation, 30 days after discharge, complete 
resolution of the dermatological manifestations was noted.
SECOND CASE
Case presentation
A 57- year- old woman with a medical history of migraine, arterial 
hypertension, chronic venous insufficiency, gastro- oesophageal 
reflux disease and obesity, initially presented with diffuse urti-
carial rash on the cervical and chest region (figures 5 and 6). 
Three days later, she developed fever, fatigue and posterior 
thoracalgia.
Investigations
Nasopharyngeal swab for SARS- CoV-2 RNA amplification came 
back positive on the day of admission to our COVID-19 ward. 
Blood test results revealed increased D- dimers (799 ng/mL), 
LDH (261 U/L), CRP (48.20 mg/dL) and ferritin (439 ng/mL). 
The white blood cells, platelet count, kidney and liver function, 
Figure 1 Erythematous–violaceous macules on the inner side of the 
right foot.
Figure 2 Erythematous–violaceous macules in the interdigital region.
Figure 3 Erythematous–violaceous macules in the interdigital region.
Figure 4 Chest radiography revealed peripheral cotton infiltrates in 
both lung bases with greater extension in the right base.
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and ionogram were all normal. There were no signs of pneu-
monia on the chest X- ray.
Treatment
Oral cetirizine was started and the pruritus improved. Low- 
molecular- weight heparin in prophylactic dose (enoxaparin) and 
paracetamol were also administered.
Outcome and follow-up
Thirty days after discharge, the patient maintained the rash, but 
without the pruritus (figures 7 and 8).
THIRD CASE
Case presentation
A 49- year- old man with a medical history of colon tubulovillous 
adenoma with high- grade dysplasia was admitted with thora-
calgia, worsening shortness of breath and dry cough. He also 
had, on the cervical and chest region, urticarial rash (figure 9), 
which started 5 days before.
Investigations
SARS- CoV-2 infection, tested for by a nasopharyngeal swab, 
was diagnosed. Laboratory tests showed lymphopenia (700/
µL), increased D- dimers (500 ng/mL), abnormal liver function 
(alanine aminotransferase 60.6 U/L, aspartate aminotransferase 
115.9 U/L and GGT 108.4 U/L), elevated LDH (316 U/L), CRP 
(106.21 mg/L) and ferritin (2886 ng/mL). Platelet count, renal 
function and ionogram were normal. Chest X- ray was negative 
for pneumonia.
Treatment
The patient was treated with prophylactic enoxaparin, cetirizine 
and paracetamol.
Outcome and follow-up
The pruritus improved, and 5 days after discharge, the urticarial 
areas completely disappeared.
DISCUSSION
The SARS- CoV-2 infection has caused numerous repercussions 
on millions of individuals worldwide, medically, financially and 
socially.2 Also, it constituted a new challenge to recognise the exten-
sive range of clinical manifestations of the disease for healthcare 
Figure 5 Urticarial rash on the cervical egion.
Figure 6 Urticarial rash on the cervical and chest region.
Figure 7 Urticarial rash 1 month after discharge.
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professionals. Despite all the information currently released on this 
virus, much remains unknown about the disease’s clinical character-
istics, including dermatological manifestations.
Articles from the beginning of the pandemic in Wuhan 
described the presence of rashes in 0.2% of 1099 confirmed 
cases of COVID-19,12 so they were considered of little relevance 
for several months.12 13 As the infection spread, reaching Europe, 
there was a vast recognition and interest in these category of 
manifestations.
The case series published by Recalcati in Lombardy1 was 
the first report of the cutaneous manifestations in COVID-19 
patients during the severe acute respiratory syndrome. In this 
study, which included 88 patients, 20.4% (n=18) had skin 
lesions. The patterns described included erythematous (77.8%), 
urticarial (16.7%) and varicella- like eruptions (5.6%).1 12 After 
this publication, similar lesions were described in multiple clin-
ical cases and case series, and other forms, such as petechiae 
lesions, perniosis- type, vasculitis, polymorphic erythema, livedo 
reticularis and reactivation of oral herpes simplex type 1 were 
also described.12 14 Although most of these rashes appear to 
emerge from the cytopathic effect of the virus, some cutaneous 
patterns may be the result of a deregulatory response by the 
immune and thrombogenic systems through the uncontrolled 
release of interferon and proinflammatory cytokines.2 12
Acral lesions, also defined as pseudochilblain, are described 
as a localised inflammatory dermatological disorder presented 
as erythematous–violaceous or purpuric macules on fingers, 
elbows, toes and the lateral aspect of the feet.6 These lesions 
have been observed to be more common in young adult patients 
with a milder disease course and manifesting after the onset of 
commonly COVID-19 symptoms.2 6 However, our patient from 
case 1, was older and, for the presence of bilateral pneumonia 
requiring oxygen therapy, SARS- CoV-2 infection was considered 
of moderate severity. Pseudochilblain eruptions are frequently 
asymmetrically distributed,15 and Galvan et al reported pain in 
32% and itches in 30% of patients.6 Our patient had these lesions 
on both feet and reported only pain on palpation. Despite Singh 
et al stating an association between these lesions and exposure to 
cold temperatures or damp, humid environments,16 most studies 
did not confirm this relationship.2 7 12 17
The urticarial rash was the first dermatological pattern 
described in patients with SARS- CoV-2 infection12 and can 
appear before cough and fever.15 In the case series published by 
Recalcati, 16.7% of the 18 patients had these lesions, slightly 
itchy and mainly distributed over the trunk.1 12 It is important to 
note that these skin changes did not correlate with the severity of 
the disease12 and were described in patients with a milder clinical 
course and limited symptoms.13 In the literature cases, this rash 
has improved with the introduction of oral antihistamines.12 15 
In our two patients with urticarial rashes, the COVID-19 had a 
Figure 8 Urticarial rash 1 month after discharge.
Figure 9 Urticarial rash on the cervical and chest region.
Learning points
 ► Acral areas of erythema–oedema with some vesicles or 
pustules (pseudochilblain), other vesicular eruptions, urticarial 
lesions, other maculopapules, and livedos or necrosis are the 
most reported cutaneous symptoms of COVID-19.
 ► Clinicians should be aware of the cutaneous manifestations 
linked to COVID-19 as they might be the presenting sign of 
infection in asymptomatic or minimally symptomatic patients.
 ► As in most of the aspects intrinsic to this new virus, much 
remains to be revealed concerning cutaneous manifestations, 
which demands further investigations.
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milder course, and the introduction of cetirizine improved the 
associated pruritus.
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